Association between initial 30‐day cumulative clozapine dose and risk of agranulocytosis: A nationwide register‐based cohort study

Yuki Kikuchi, Xue Li, Hiroshi Komatsu, Norio Yasui‐Furukori, Ken Inada, Hiroaki Tomita · 2026

Read Association between initial 30‐day cumulative clozapine dose and risk of agranulocytosis: A nationwide register‐based cohort study by Yuki Kikuchi, Xue Li, Hiroshi Komatsu, Norio Yasui‐Furukori, Ken Inada, Hiroaki Tomita (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13537344.txt.

Description

Yuki Kikuchi and co-authors test whether early total clozapine dose predicts a severe drop in infection-fighting white cells in a 2026 nationwide Japanese study. Clozapine helps treatment-resistant schizophrenia yet carries this rare blood risk, long thought unrelated to dose. Registry data from 2009 to 2024 covered 18,189 starters, grouped by total dose in the first thirty days. Later blood events were compared across dose quarters.

No events occurred in the first thirty days, and later rates rose steadily from the lowest to the highest dose quarter. Highest-quarter patients faced about triple the risk of lowest-quarter patients over six months. Male sex and age over forty years also raised risk on their own. The authors suggest early total dose as a useful risk marker, while noting that cause remains unproven.

Catalog record

CREATORYuki Kikuchi, Xue Li, Hiroshi Komatsu, Norio Yasui‐Furukori, Ken Inada, Hiroaki Tomita
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE40730
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13537344

Browse the full library · About the Tower of Babel